What to Do If You Have COVID: Treat and Recover

Most people with COVID-19 recover at home with rest, fluids, over-the-counter fever reducers, and close attention to warning signs that would warrant medical help. If you are at higher risk for severe illness, prescription antivirals like Paxlovid can substantially cut your chances of hospitalization when started early. The path from a positive test to feeling like yourself again involves a handful of practical decisions, and the timing of those decisions matters more than most people realize.

Confirming You Actually Have It

Rapid antigen tests are widely available and work well in the first week of symptoms. When researchers evaluated multiple rapid antigen platforms, sensitivity hit 100% for most brands during the first six days of symptoms in people with high viral loads.¹ That said, a single test on the first day of symptoms can miss an infection. If your first test is negative but you feel sick, test again 48 hours later. Serial testing two days apart pushes sensitivity above 93% in symptomatic people during the first week.²

Swabbing technique affects accuracy too. A large cross-sectional study during the Omicron wave found that combining a throat and nasal swab improved sensitivity compared to a nasal swab alone, especially in people who were not already suspicious they had COVID. Among those testing for general screening rather than to confirm suspected infection, the combined approach caught roughly 69% of infections compared to about 60% with nasal-only sampling.³ So if you are testing yourself at home, swab the back of your throat first, then both nostrils, if the test instructions allow for it.

Getting Antiviral Treatment Quickly

The single most time-sensitive decision after a positive test is whether you qualify for antiviral medication and can start it fast. These drugs work by blocking viral replication, and every day of delay erodes their benefit.

Paxlovid (nirmatrelvir/ritonavir) is the frontline oral antiviral for outpatients at higher risk. Mathematical modeling of hospitalized patients estimated it can inhibit over 90% of viral replication, but its effectiveness drops sharply if treatment starts after day five of symptoms.⁴ In head-to-head viral clearance comparisons, Paxlovid cleared virus roughly 84% faster than no treatment, with a median viral clearance half-life of about 8.5 hours compared to 15.5 hours with no drug.⁵ The practical takeaway: call your doctor or use a telehealth service the same day you test positive. Do not wait to see if you feel worse.

Remdesivir is an IV antiviral originally developed for hospitalized patients, but it also works for high-risk outpatients given as a three-day infusion. In a randomized trial, hospitalization or death occurred in under 1% of the remdesivir group versus about 5% in placebo, an 87% relative reduction.⁶ A real-world prospective cohort confirmed the effect, with remdesivir cutting the odds of hospitalization or death by a similar margin.⁷ The catch is that you need three consecutive days of IV infusions at a clinic, which is logistically harder than swallowing pills at home. Your doctor may recommend it if Paxlovid is not an option due to drug interactions.

Molnupiravir is another oral antiviral, but the evidence for it has weakened over time. Its initial interim trial showed a halving of hospitalizations, but the final analysis of all participants showed a smaller and less convincing benefit.⁸ A systematic review and meta-analysis later concluded that molnupiravir probably does not significantly reduce hospitalization or death compared to standard care.⁹ In the head-to-head platform trial, molnupiravir cleared virus 25% more slowly than Paxlovid and was ultimately removed from the study for meeting the inferiority threshold.⁵ Molnupiravir is a fallback, not a first choice.

Drug Interactions With Paxlovid

One of the reasons Paxlovid is not prescribed to everyone is that it contains ritonavir, a compound that powerfully inhibits certain liver enzymes involved in breaking down many common medications. This creates a high potential for harmful drug interactions.¹⁰ Some medications must be paused, some need dose adjustments, and a few are outright contraindicated. Blood thinners, certain heart medications, immunosuppressants, and some psychiatric drugs are among the categories most affected.¹¹

This is why your prescriber needs a complete and accurate medication list. Do not assume an over-the-counter supplement or an old prescription does not matter. If you take multiple medications and your doctor is uncertain, a pharmacist can run an interaction check. In many cases, briefly pausing a medication for the five-day Paxlovid course is safe and worth the tradeoff, but that judgment has to be made case by case.

Pregnant people face an additional layer of uncertainty. Most phase III clinical trials of COVID antivirals excluded pregnant participants, so the safety data comes mostly from theoretical risk assessment and limited observational reports rather than rigorous trials.¹² If you are pregnant and test positive, discuss risks and benefits with your OB provider. The conversation is not straightforward, but COVID itself carries real risks in pregnancy too, so avoiding treatment entirely may not be the safer option.

Managing Symptoms at Home

For most people, COVID means several days of fever, body aches, sore throat, congestion, cough, and fatigue. Standard over-the-counter pain relievers handle the fever and aches. Early in the pandemic, there was concern that ibuprofen might worsen outcomes, but multiple studies have put that fear to rest. In a cohort of COVID patients, ibuprofen users showed no difference in mortality or need for breathing support compared to those taking acetaminophen.¹³ A nationwide population-based study confirmed that clinical outcomes did not differ between the two drug classes.¹⁴ Use whichever you tolerate better, following the dosing on the label.

Hydration matters more than people tend to think. Fever, sweating, and reduced appetite all push you toward dehydration, which makes headaches worse and can thicken mucus. There is no magic amount, but if your urine is dark, you are behind. Water, broth, electrolyte drinks, and tea are all fine. A small hospital-based trial found that targeted hydration of the upper airway using a specific nebulized solution led to significant improvements in oxygen saturation and faster symptom resolution compared to plain saline, though this particular approach is not yet widely available for home use.¹⁵

If you are coughing and feel short of breath, try lying on your stomach. “Awake proning,” as it is called, has become a standard recommendation for COVID patients with breathing difficulty. A prospective study found it was associated with better oxygenation and lower rates of ICU admission.¹⁶ In a randomized crossover trial, prone positioning improved the ratio of oxygen in arterial blood more than twofold and reduced respiratory rate from about 26 breaths per minute to 21.¹⁷ You do not need medical equipment for this. If breathing feels labored, roll onto your stomach, prop yourself comfortably with pillows, and stay that way for 30 minutes to a couple of hours at a time. It is a low-risk intervention that can buy meaningful comfort.¹⁸

Nasal Rinsing and Gargling

Saline nasal irrigation is an inexpensive, low-tech intervention that has quietly built a reasonable evidence base during the pandemic. A multidisciplinary review found that both single-day and repeated saline rinses reduce viral loads in the nose and throat.¹⁹ A systematic review of nasal irrigation studies found that nine out of ten studies using saline-based solutions reported positive effects on reducing viral load, with benefits including earlier negative PCR tests and greater drops in virus during the first days of treatment.²⁰ Both isotonic and hypertonic saline worked, and some studies found additives improved results further.

This is not a cure, and nobody should skip antivirals in favor of a neti pot. But rinsing your sinuses two to three times a day with saline while you are sick is safe, cheap, and may help clear virus faster while also relieving congestion. Use distilled or previously boiled water, not straight tap water, to avoid introducing other pathogens into your sinuses.

Warning Signs That Mean You Need Medical Help

Most COVID illness stays mild enough to manage at home. The danger zone is silent hypoxia, where your blood oxygen drops before you feel dramatically short of breath. A home pulse oximeter costs little and can catch this early. In one study, five out of six patients who ended up hospitalized said it was a low pulse oximeter reading that prompted them to seek care. Meanwhile, 96% of those who stayed home said having the device gave them confidence they were safe.²¹ If you are in a higher-risk group, picking up an FDA-approved pulse oximeter is one of the best investments you can make.²²

Call your doctor or go to the emergency room if you experience any of the following:

Oxygen reading below 94%: Persistent readings below this level, especially if trending downward, indicate your lungs are struggling.
Difficulty breathing: Feeling winded at rest or while doing things like walking to the bathroom.
Persistent chest pain or pressure: Not the fleeting aches of a cough, but sustained tightness.
Confusion or difficulty staying awake: A sign your brain may not be getting enough oxygen.
Bluish lips or face: Another sign of very low oxygen.
Inability to keep fluids down: Severe nausea or vomiting that prevents hydration.

Research on predictors of severe illness has found that age above 63 and elevated inflammatory markers are independent risk factors for deterioration.²³ You cannot check your own blood markers at home, but you can track your oxygen, temperature, and subjective breathing comfort. If any of these worsen after initially improving, or if you hit day seven to ten and suddenly feel worse rather than better, treat that as a red flag.

Paxlovid Rebound

Some people who take Paxlovid feel better, test negative, and then a few days later develop symptoms again and test positive. This “rebound” phenomenon is real, though the exact frequency varies between studies. One prospective cohort found viral rebound in about 14% of Paxlovid users compared to 9% of untreated controls, with symptom rebound in about 19% versus 7%.²⁴ A larger study put the virologic rebound rate closer to 21% in Paxlovid users, with rebound cases shedding virus for an average of 14 days, compared to under 5 days for those who did not rebound.²⁵

Modeling work helps explain why. If Paxlovid is started very early, it suppresses the virus before the immune system has fully ramped up, so when the drug course ends after five days, residual virus can flare back.⁴ Rebound does not mean the drug failed. It still provided the initial benefit of reducing peak viral load and lowering the risk of severe disease. But if you rebound, you should consider yourself potentially contagious again and resume isolation precautions. You do not need a second course of Paxlovid for rebound; symptoms typically resolve on their own within a few days.

Easing Back Into Activity

One of the most common mistakes people make after acute COVID is returning to their usual level of physical and mental activity too fast. Even after mild cases, the body’s recovery trajectory is not linear. Pushing too hard too soon can trigger what researchers call post-exertional symptom exacerbation, where exercise, cognitive effort, or even emotional stress brings back fatigue, brain fog, or body aches hours to days later.

A structured pacing protocol based on a gradual five-phase approach showed striking results: participants went from an average of 3.4 post-exertional flare-ups per week to 1.1 over six weeks, with reductions across physical, cognitive, and emotional triggers.²⁶ Pacing adherence turns out to be one of the strongest predictors of recovery. Patients who closely followed pacing guidelines were dramatically more likely to recover than those who did not.²⁷

What does pacing look like in practice? Start below what you think you can handle. If you could walk for 20 minutes before getting sick, start with 10 and see how you feel the next day. Increase by small increments only if you had no symptom flare. A review of post-viral fatigue interventions also found that strengthening exercises are better tolerated than endurance activities like running or cycling during recovery, and that home-based activities integrated into your daily routine tend to work better than gym-based programs.²⁸ The evidence is consistent: patience during recovery is not laziness. It is the strategy most associated with getting back to normal.

Can Early Treatment Reduce Your Risk of Long COVID?

Whether antivirals taken during acute illness protect against long COVID is one of the most actively studied questions right now. The results are encouraging but not yet dramatic. A large observational study from the RECOVER Initiative found that Paxlovid treatment was associated with a modest reduction in long COVID risk, with about 3 fewer cases per 100 people treated.²⁹ A separate analysis from the same research consortium found Paxlovid did not significantly reduce overall long COVID incidence but did have a small protective effect against cognitive symptoms and fatigue specifically.³⁰

A randomized, placebo-controlled trial from Norway offered more encouraging numbers: long COVID at three months was reported in 26% of the Paxlovid group versus 43% in the placebo group, a 40% relative risk reduction.³¹ The researchers noted, though, that the sample was small and further trials are needed. The picture that is forming suggests that Paxlovid likely offers some protection against long COVID, particularly for fatigue and cognitive symptoms, but it is not a guarantee. This is one more reason to get treatment early if you qualify, on top of the already clear benefit of preventing hospitalization.

Immunity After Infection and Staying Up to Date

After recovering from COVID, you do have some natural immunity, but how much and for how long depends heavily on whether you have also been vaccinated. A large study tracking protection over time found that immunity from infection alone waned after about a year in unvaccinated people. In those who were later vaccinated, protection remained above 90% even 18 months after their original infection.³² The combination of infection plus vaccination, sometimes called hybrid immunity, produces a broader and more durable immune response than either alone.

Newer variants complicate things further. Research on long-term antibody responses found that neutralizing antibodies were highest against the original virus strain and declined against successive Omicron subvariants. A fourth vaccine dose combined with a breakthrough infection produced the strongest antibody response across all variants tested.³³ The practical upshot: even after recovering from COVID, staying current with updated vaccines gives your immune system the best shot at recognizing whatever variant comes next. You do not need to rush to get vaccinated while you are still sick, but once you have fully recovered, check whether you are due for a dose.

When Is It Safe to Stop Isolating?

Official isolation guidance has shifted over the course of the pandemic, and the current recommendations in most places are less strict than they were in 2020 and 2021. But biology has not changed. Rapid antigen tests can help you gauge whether you are still likely to be contagious. Research into optimal isolation strategies found that when a test’s detection limit is above the actual threshold for infectiousness, a single negative test is not enough to confirm you are no longer contagious. Additional consecutive negatives strengthen the conclusion.³⁴

A reasonable approach: once your symptoms have improved and you have been fever-free for at least 24 hours without medication, take a rapid test. If it is negative, you are likely no longer contagious. If it is still positive, wait another day or two and test again. People who experienced Paxlovid rebound should apply this same logic from the start of their rebound symptoms. Wearing a well-fitting mask around others for a few days after your last positive test or the end of symptoms adds an extra layer of protection, especially around vulnerable household members.

1
PubMed Central. Time scale performance of rapid antigen testing for SARS-CoV-2: Evaluation of 10 rapid antigen assays
2
PubMed Central. Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection: A Prospective Cohort Study
3
BMJ. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-sampling in people with symptoms in the omicron period: cross sectional study
4
PubMed Central. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
5
The Lancet Infectious Diseases. Comparative in-vivo antiviral activity of molnupiravir and ritonavir-boosted nirmatrelvir in patients with early COVID-19 (PLATCOV)
6
PubMed. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
7
PubMed Central. Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study
8
PubMed Central. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
9
Journal of Antimicrobial Chemotherapy. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
10
PubMed Central. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
11
PubMed Central. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences
12
PubMed Central. COVID-19 Therapeutics and Considerations for Pregnancy
13
PubMed Central. Ibuprofen use and clinical outcomes in COVID-19 patients
14
PubMed Central. Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study
15
Scientific Reports. COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea
16
PubMed Central. Effectiveness of prone position in spontaneously breathing patients with COVID-19: A prospective cohort study
17
PubMed Central. Physiologic Effects of the Awake Prone Position Combined With High-Flow Nasal Oxygen on Gas Exchange and Work of Breathing in Patients With Severe COVID-19 Pneumonia
18
PubMed Central. Awake Proning: Current Evidence and Practical Considerations
19
PubMed Central. Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes
20
PubMed Central. Washing Illness Away: A Systematic Review of the Impact of Nasal Irrigation and Spray on COVID-19
21
PubMed Central. Use of home pulse oximetry with daily short message service messages for monitoring outpatients with COVID-19
22
PubMed Central. Home Pulse Oximetry Monitoring during the COVID-19 Pandemic: An Assessment of Patient Engagement and Compliance
23
PLOS ONE. Analysis of clinical features and early warning signs in patients with severe COVID-19: A retrospective cohort study
24
medRxiv. The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
25
Annals of Internal Medicine. One in Five Patients Experience Rebound COVID After Taking Paxlovid, New Study Finds
26
PubMed Central. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome
27
PubMed Central. The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome
28
PLOS ONE. A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?
29
PubMed Central. Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – A Large-Scale Observational Cohort Study from the RECOVER Initiative
30
PubMed Central. Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia
31
PubMed. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway)
32
PubMed. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
33
PubMed Central. Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity
34
Nature Communications. Designing isolation guidelines for COVID-19 patients with rapid antigen tests